Patents by Inventor Keiko Kawamoto
Keiko Kawamoto has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 9085611Abstract: Provided are a humanized monoclonal antibody against PcrV or a part thereof, and a pharmaceutical composition containing the same as an active ingredient, as an effective means for therapy of infection, particularly infection with Pseudomonas aeruginosa. Concretely, the humanized monoclonal antibody of the present invention has an excellent inhibitory activity on the cytotoxicity with respect to a target cell of Pseudomonas aeruginosa. Also, the humanized monoclonal antibody of the present invention has a high affinity for PcrV.Type: GrantFiled: January 4, 2013Date of Patent: July 21, 2015Assignee: SHIONOGI & CO., LTD.Inventors: Yoshinori Yamano, Yoshito Numata, Takafumi Sato, Toshinaga Tsuji, Keiko Kawamoto
-
Patent number: 9080180Abstract: A technology for producing a pig edema disease vaccine at low cost and at high efficiency is developed. Specifically, a gene of a pig edema disease toxin protein (Stx2e protein) is efficiently expressed in plant cells to produce a plant vaccine for pig edema disease at low cost. An Stx2e protein including a secretory signal peptide derived from a plant added at an amino terminus is expressed in cells of a plant such as Lactuca sativa using the 5?-untranslated region of an alcohol dehydrogenase gene (ADH5?UTR) derived from a plant.Type: GrantFiled: March 25, 2008Date of Patent: July 14, 2015Assignees: IDEMITSU KOSAN CO., LTD., NATIONAL UNIVERSITY CORPORATION NARA INSTITUTE OF SCIENCE AND TECHNOLOGY, NATIONAL UNIVERSITY CORPORATION OBIHIRO UNIVERSITY OF AGRICULTURE AND VETERINARY MEDICINEInventors: Kazutoshi Sawada, Takeshi Matsui, Sou-ichi Makino, Keiko Kawamoto, Mayumi Yoshida, Nobuo Yoshida, Kyoko Yoshida
-
Patent number: 8883977Abstract: An objective of the present invention is to provide a MUC1 antibody having high specificity to cancer cells. The objective has been achieved by the present inventors who found that a cancer-specific sugar chain can be specifically recognized in MUC1 and a cancer cell expressing MUC1 having such a cancer cell specific sugar chain can be recognized. The present invention provides an antibody, an antigen-binding fragment thereof or a MUC1-binding molecule, having, for example, 40-fold specificity or more for a cancer-associated structure of MUC1 as compared to that of a normal tissue-associated structure of MUC1.Type: GrantFiled: April 28, 2011Date of Patent: November 11, 2014Assignees: Shionogi & Co., Ltd., National University Corporation Hokkaido UniversityInventors: Shin-Ichiro Nishimura, Shoichi Naito, Naoki Ohyabu, Tatsuya Takahashi, Yoshito Numata, Keiko Kawamoto
-
Publication number: 20120093808Abstract: Provided are a humanized monoclonal antibody against PcrV or a part thereof, and a pharmaceutical composition containing the same as an active ingredient, as an effective means for therapy of infection, particularly infection with Pseudomonas aeruginosa. Concretely, the humanized monoclonal antibody of the present invention has an excellent inhibitory activity on the cytotoxicity with respect to a target cell of Pseudomonas aeruginosa. Also, the humanized monoclonal antibody of the present invention has a high affinity for PcrV.Type: ApplicationFiled: March 9, 2010Publication date: April 19, 2012Applicant: Shionogi & Co., Ltd.Inventors: Yoshinori Yamano, Yoshito Numata, Takafumi Sato, Toshinaga Tsuji, Keiko Kawamoto
-
Publication number: 20110002950Abstract: A technology for producing a pig edema disease vaccine at low cost and at high efficiency is developed. Specifically, a gene of a pig edema disease toxin protein (Stx2e protein) is efficiently expressed in plant cells to produce a plant vaccine for pig edema disease at low cost. An Stx2e protein including a secretory signal peptide derived from a plant added at an amino terminus is expressed in cells of a plant such as Lactuca sativa using the 5?-untranslated region of an alcohol dehydrogenase gene (ADH5?UTR) derived from a plant.Type: ApplicationFiled: March 25, 2008Publication date: January 6, 2011Applicants: IDEMITSU KOSAN CO., LTD, NAT. UNI. CORP. NARA INSTITUTE OF SCI. AND TECH., NAT UNI CORP OBIHIRO UNI OF AGRI AND VET MEDInventors: Kazutoshi Sawada, Kazuya Yoshida, Mayumi Yoshida, Nobuo Yoshida, Kyoko Yoshida, Takeshi Matsui, Sou-ichi Makino, Keiko Kawamoto
-
Publication number: 20060040255Abstract: A cell line KT-1 isolated from mouse tongue epithelium using high-level expression of integrin ?1 as the indicator and established by a long time culture, and which expresses a taste receptor; a taste sensor comprising the cell line KT-1; the use of the cell line KT-1 to search for a factor which induces differentiation of taste cells, a substance which controls expression of taste receptors, a novel taste substance, a taste-modifying substance and a substance which aids in taste-suppressed state.Type: ApplicationFiled: September 30, 2005Publication date: February 23, 2006Inventors: Tetsuya Ookura, Keiko Kawamoto, Akihiro Hino
-
Patent number: 6899893Abstract: This invention is to provide an agent for therapy and prevention of allergic diseases which has no adverse action, shows a high safety even by administration for a long period and is able to be utilized to food and/or beverage, cosmetics, etc. which are used daily. To be specific, it provides antiallergic agent and anti-inflammatory agent characterized in containing at least one polyphenol selected from strictinin and methylated derivatives thereof as an effective ingredient; a method for the addition of an antiallergic agent for oral administration or an anti-inflammatory agent for oral administration which is characterized in containing at least one polyphenol selected from strictinin and methylated derivatives thereof as an effective ingredient to food and/or beverage for prevention, suppression and mitigation of allergic symptoms or inflammatory symptoms.Type: GrantFiled: April 17, 2003Date of Patent: May 31, 2005Assignees: National Agriculture Research Organization, Bio-oriented Technology Research Advancement InstitutionInventors: Kenkou Tsuji, Mari Yamamoto, Keiko Kawamoto, Hirofumi Tachibana
-
Patent number: 6638524Abstract: This invention is to provide an agent for therapy and prevention of allergic diseases which has no adverse action, shows a high safety even by administration for a long period and is able to be utilized to food and/or beverage, cosmetics, etc. which are used daily. To be specific, it provides antiallergic agent and anti-inflammatory agent characterized in containing at least one polyphenol selected from strictinin and methylated derivatives thereof as an effective ingredient; a method for the addition of an antiallergic agent for oral administration or an anti-inflammatory agent for oral administration which is characterized in containing at least one polyphenol selected from strictinin and methylated derivatives thereof as an effective ingredient to food and/or beverage for prevention, suppression and mitigation of allergic symptoms or inflammatory symptoms.Type: GrantFiled: April 25, 2002Date of Patent: October 28, 2003Assignees: National Agricultural Research Organization, Bio-oriented Technology Research Advancement InstitutionInventors: Kenkou Tsuji, Mari Yamamoto, Keiko Kawamoto, Hirofumi Tachibana
-
Publication number: 20030165558Abstract: This invention is to provide an agent for therapy and prevention of allergic diseases which has no adverse action, shows a high safety even by administration for a long period and is able to be utilized to food and/or beverage, cosmetics, etc. which are used daily. To be specific, it provides antiallergic agent and anti-inflammatory agent characterized in containing at least one polyphenol selected from strictinin and methylated derivatives thereof as an effective ingredient; a method for the addition of an antiallergic agent for oral administration or an anti-inflammatory agent for oral administration which is characterized in containing at least one polyphenol selected from strictinin and methylated derivatives thereof as an effective ingredient to food and/or beverage for prevention, suppression and mitigation of allergic symptoms or inflammatory symptoms.Type: ApplicationFiled: April 17, 2003Publication date: September 4, 2003Applicant: National Agricultural Research Org.Inventors: Kenkou Tsuji, Mari Yamamoto, Keiko Kawamoto, Hirofumi Tachibana
-
Publication number: 20030003121Abstract: This invention is to provide an agent for therapy and prevention of allergic diseases which has no adverse action, shows a high safety even by administration for a long period and is able to be utilized to food and/or beverage, cosmetics, etc. which are used daily. To be specific, it provides antiallergic agent and anti-inflammatory agent characterized in containing at least one polyphenol selected from strictinin and methylated derivatives thereof as an effective ingredient; a method for the addition of an antiallergic agent for oral administration or an anti-inflammatory agent for oral administration which is characterized in containing at least one polyphenol selected from strictinin and methylated derivatives thereof as an effective ingredient to food and/or beverage for prevention, suppression and mitigation of allergic symptoms or inflammatory symptoms.Type: ApplicationFiled: April 25, 2002Publication date: January 2, 2003Applicant: National Agricultural Research Org.Inventors: Kenkou Tsuji, Mari Yamamoto, Keiko Kawamoto, Hirofumi Tachibana
-
Patent number: 6491943Abstract: This invention is to provide an agent for therapy and prevention of allergic diseases which has no adverse action, shows a high safety even by administration for a long period and is able to be utilized to food and/or beverage, cosmetics, etc. which are used daily. To be specific, it provides antiallergic agent and anti-inflammatory agent characterized in containing at least one polyphenol selected from strictinin and methylated derivatives thereof as an effective ingredient; a method for the addition of an antiallergic agent for oral administration or an anti-inflammatory agent for oral administration which is characterized in containing at least one polyphenol selected from strictinin and methylated derivatives thereof as an effective ingredient to food and/or beverage for prevention, suppression and mitigation of allergic symptoms or inflammatory symptoms.Type: GrantFiled: February 8, 2001Date of Patent: December 10, 2002Assignee: National Agricultural Research OrganizationInventors: Kenkou Tsuji, Mari Yamamoto, Keiko Kawamoto, Hirofumi Tachibana
-
Publication number: 20020168397Abstract: This invention is to provide an agent for therapy and prevention of allergic diseases which has no adverse action, shows a high safety even by administration for a long period and is able to be utilized to food and/or beverage, cosmetics, etc. which are used daily. To be specific, it provides antiallergic agent and anti-inflammatory agent characterized in containing at least one polyphenol selected from strictinin and methylated derivatives thereof as an effective ingredient; a method for the addition of an antiallergic agent for oral administration or an anti-inflammatory agent for oral administration which is characterized in containing at least one polyphenol selected from strictinin and methylated derivatives thereof as an effective ingredient to food and/or beverage for prevention, suppression and mitigation of allergic symptoms or inflammatory symptoms.Type: ApplicationFiled: February 8, 2001Publication date: November 14, 2002Inventors: Kenkou Tsuji, Mari Yamamoto, Keiko Kawamoto, Hirofumi Tachibana